KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) Tax Provisions (2016 - 2026)

Boston Scientific's Tax Provisions history spans 18 years, with the latest figure at -$176.0 million for Q1 2026.

  • On a quarterly basis, Tax Provisions fell 232.33% to -$176.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $183.0 million, a 59.69% decrease, with the full-year FY2025 number at $493.0 million, up 13.07% from a year prior.
  • Tax Provisions hit -$176.0 million in Q1 2026 for Boston Scientific, down from $30.0 million in the prior quarter.
  • Over the last five years, Tax Provisions for BSX hit a ceiling of $255.0 million in Q4 2022 and a floor of -$176.0 million in Q1 2026.
  • Historically, Tax Provisions has averaged $93.4 million across 5 years, with a median of $105.0 million in 2023.
  • Biggest five-year swings in Tax Provisions: soared 2200.0% in 2024 and later plummeted 232.33% in 2026.
  • Tracing BSX's Tax Provisions over 5 years: stood at $255.0 million in 2022, then plummeted by 99.61% to $1.0 million in 2023, then soared by 2200.0% to $23.0 million in 2024, then surged by 30.43% to $30.0 million in 2025, then tumbled by 686.67% to -$176.0 million in 2026.
  • Business Quant data shows Tax Provisions for BSX at -$176.0 million in Q1 2026, $30.0 million in Q4 2025, and $183.0 million in Q3 2025.